Peter Beaudoin Hosts Chris Bladen (Zymedyne Therapeutics) on the LIBI Podcast

Published: Feb. 22, 2022, 3 p.m.

b'Join host Peter Beaudoin as he explores the growing health sector with Chris Bladen, CEO and Co-founder of Zymedyne Therapeutics, a Calgary based company that is developing more effective treatments for chronic pain.\\nFor the transcription of this episode please visit: https://www.rainforestab.ca/yyc-blog/podcast-episode-158-transcription\\nThank you for listening to the Leaders, Innovators and Big Ideas podcast, supported by\\xa0Rainforest Alberta. The podcast that highlights those people who are contributing to and/or supporting the innovation ecosystem in Alberta.Host: Peter Beaudoin\\xa0Peter manages strategy and partnerships for an innovative alliance of energy companies committed to reducing environmental impacts through collaborative R&D efforts. Peter worked for more than 20 years in Asia building and investing in a variety of businesses. His most recent role outside of Canada was with the World Wildlife Fund, where he was the Chief Executive Officer of WWF China, based in Beijing. Prior to that, Peter lived in Hong Kong for 15 years working in the technology industry.\\nGuest: Dr. Chris Bladen\\xa0received his PhD in Molecular Neuroscience from the Hotchkiss Brain Institute, University of Calgary in 2014. His thesis was based on using Electrophysiology and Molecular Biology to develop drugs and small molecules for Pain and Epilepsy research as well as other clinical purposes. He has a B.Sc. in Freshwater Chemistry and a degree in Environmental management and has extensive experience in both academia and industry. His previous work experience includes several years as an independent environmental consultant for the oil and gas industry in Alberta and several years working in the biopharma industry. \\xa0He has developed a world-wide collaborative network in the fields of Electrophysiology, Molecular Biology and Drug design. In addition to being CEO of Zymedyne therapeutics, he is currently an (Online) Lecturer at Macquarie University\\u2019s Department of Biomedical Sciences, where he teaches Pharmacology and conducts research into the therapeutic potential of Synthetic and Phyto Cannabinoids.\\nPlease be sure to share this episode with everyone you know. If you are interested in being either a host, a guest, or a sponsor of the show, please reach out. We are published in Google Podcasts\\xa0and the\\xa0iTunes store for Apple Podcasts We would be grateful if you could give us a rating as it helps spread the word about the show.\\nShow Quotes:\\n"[Big Pharma] see smaller biopharma companies, such as ourselves as being much more nimble in the R and D space. So they look to partner with multiple small biopharma and their ideas, and then take some of those ideas and they do what they they\'re good at, which is the latest stage clinical trial planning phases. And of course the FDA approval marketing."\\nCredits...This Episode Sponsored By: Assembly Coworking SpaceEpisode Music:\\xa0Tony Del DeganCreator & Producer:\\xa0Al Del Degan'